Difference between revisions of "Irinotecan (Camptosar)"

Revision as of 13:00, 10 December 2021

General information

Class/mechanism: Topoisomerase I inhibitor; derivative of camptothecin, which interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I & DNA complex and interfere with ligation of these single-strand breaks. Failure to repair these breaks eventually leads to double-strand DNA damage, which disrupts cell proliferation and leads to cell death.^[1]^[2]
Route: IV
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

6/14/1996: Initial accelerated approval for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy.
- 10/22/1998: Converted to regular approval.
4/20/2000: Indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum.
4/20/2000: Also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.

Also known as

Code names: Camptothecin-11, CPT-11, U-101440E
Brand names: Axinotecan, Biotecan, Biskam, Campto, Campostar, Camptosar, Elinatecan, Faultenocan, Irenax, Irinogen, Irinomedac, Irinotel, Irinotesin, Irnocam, Itoxaril, Linatecan, Onivyde, Satigene, Tecnotecan, Tekamen, Toptecin, Trinotecan, Winol

References

[insert-1] 1.0 ^1.1 ^1.2 Irinotecan (Camptosar) package insert

[2] Irinotecan (Camptosar) package insert (locally hosted backup)

[3] Irinotecan (Camptosar) patient drug information (Chemocare)

[4] Irinotecan (Camptosar) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 31: / Line 31: @@
 ==History of changes in FDA indication==
 * 6/14/1996: Initial accelerated approval for the treatment of patients with metastatic carcinoma of the [[Colon cancer | colon]] or [[Rectal cancer | rectum]] whose disease has recurred or progressed following [[Fluorouracil (5-FU) | 5-FU-based]] therapy.
-*10/22/1998: Converted to regular approval.
+**10/22/1998: Converted to regular approval.
 * 4/20/2000: Indicated as a component of first-line therapy in combination with [[Fluorouracil (5-FU) | 5-fluorouracil]] and [[Folinic acid (Leucovorin) | leucovorin]] for patients with metastatic carcinoma of the [[Colon cancer | colon]] or [[Rectal cancer | rectum]].
 * 4/20/2000: Also indicated for patients with metastatic carcinoma of the [[Colon cancer | colon]] or [[Rectal cancer | rectum]] whose disease has recurred or progressed following initial [[Fluorouracil (5-FU) | fluorouracil-based]] therapy.